ONO 7475

Drug Profile

ONO 7475

Alternative Names: ONO 7475

Latest Information Update: 26 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ono Pharmaceutical
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto-oncogene protein c-mer inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia
  • Preclinical Solid tumours

Most Recent Events

  • 21 Apr 2018 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 01 Jan 2017 Phase-I clinical trials in Acute myeloid leukaemia (Newly diagnosed, Second-line therapy or greater) in USA (PO) (NCT03176277)
  • 01 Jan 2017 Preclinical trials in Solid tumours in USA (SC) before January 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top